SCHEMBL16097664

SCHEMBL16097664

CC(=O)N[C@@H](CSCCC(=O)O)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ KDM4E B2RXH2 1/20 0.48
▸ THRB P10828 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ PTGS2 P35354 1/20 0.48
▸ THPO P40225 1/20 0.48
▸ RECQL P46063 1/20 0.48
▸ BLM P54132 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ LMNA P02545 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ FOLH1 Q04609 6/20 0.44
▸ NAALAD2 Q9Y3Q0 2/20 0.44
▸ RIMKLA Q8IXN7 1/20 0.44
▸ ICMT O60725 1/20 0.41
▸ GNPAT O15228 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11553457 1.00 MAPT (0.51) MAPTALDH1A1KDM4ETHRBALOX15
SCHEMBL11552647 0.88 MAPT (0.48) MAPTALDH1A1KDM4ETHRBALOX15
SCHEMBL20213764 0.86 MAPT (0.49) MAPTALDH1A1KDM4ETHRBALOX15
SCHEMBL20213762 0.86 MAPT (0.49) MAPTALDH1A1KDM4ETHRBALOX15
SCHEMBL21144523 0.85 MAPT (0.52) MAPTALDH1A1KDM4ETHRBALOX15
SCHEMBL30416885 0.85 SMN1; SMN2 (0.43) MAPTALDH1A1KDM4ETHRBALOX15
SCHEMBL16745722 0.85 MAPT (0.59) MAPTALDH1A1KDM4ETHRBALOX15
SCHEMBL31405642 0.85 MAPT (0.59) MAPTALDH1A1KDM4ETHRBALOX15
SCHEMBL6308419 0.85 MAPT (0.59) MAPTALDH1A1KDM4ETHRBALOX15
SCHEMBL14991078 0.84 MAPT (0.50) MAPTALDH1A1KDM4ETHRBALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028489-A1 SUPPORTED POLYMERIZATION INHIBITORS AND THEIR USE IN CURABLE COMPOSITIONS FOR 3D PRINTING ALIGN TECHNOLOGY INC (US) 2026-01-29 — — US claimed
EP-4680229-A2 METHODS OF USE AND COMPOSITIONS OF BISBENZYLISOQUINOLINES FOR THE TREATMENT OF MALIGNANCIES Cenovari Therapeutics, Inc. (US) 2026-01-21 — — EP claimed
US-12467057-B2 Methods for modifying plastid genomes MONSANTO TECHNOLOGY LLC (US) 2025-11-11 — — US claimed
US-20250197658-A1 ANTIOXIDANT STABILIZERS FOR DIRECT FABRICATION OF ORTHODONTIC APPLIANCES ALIGN TECHNOLOGY, INC. 2025-06-19 — — US claimed
US-20250179305-A1 LASER MARKABLE RESIN COMPOSITIONS FOR ORTHODONTIC APPLIANCES ALIGN TECHNOLOGY, INC. 2025-06-05 — — US claimed
US-20250179236-A1 POLYETHER-CONTAINING POLYMERIZABLE COMPOUNDS AND USE IN CURABLE RESIN COMPOSITIONS ALIGN TECHNOLOGY, INC. 2025-06-05 — — US claimed
CN-120009437-A Method for simultaneously measuring multiple volatile organic compounds metabolites in urine 中国疾病预防控制中心环境与健康相关产品安全所 2025-05-16 — — CN claimed
CN-119895425-A Electronic device for displaying image and operating method of electronic device 三星电子株式会社 2025-04-25 — — CN claimed
EP-4528576-A1 ELECTRONIC DEVICE FOR DISPLAYING IMAGE AND OPERATION METHOD OF ELECTRONIC DEVICE Samsung Electronics Co., Ltd. (KR) 2025-03-26 — — EP claimed
EP-3574326-B1 DIAGNOSTIC TEST FOR DISTINGUISHING THE SMOKING STATUS OF A SUBJECT PHILIP MORRIS PRODUCTS SA (CH) 2025-03-19 — — EP claimed
US-20220403127-A1 MIXED-CHARGE COPOLYMER ANTIBIOFILM COATINGS NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2022-12-22 — — US claimed
CN-217755302-U CEMA tubular belt conveyor 温伟杰 2022-11-08 — — CN claimed
CN-114676534-A Island microgrid planning method based on non-perfect information dynamic game 重庆大学 2022-06-28 — — CN claimed
CN-114539467-A Preparation method and adsorption application of post-crosslinked molecularly imprinted polymer 江苏大学 2022-05-27 — — CN claimed
US-20200141933-A1 DIAGNOSTIC TEST FOR DISTINGUISHING THE SMOKING STATUS OF A SUBJECT PHILIP MORRIS PRODUCTS S.A. (CH) 2020-05-07 — — US claimed
EP-2976061-B1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS DENTALMED PHARM HOLDING LTD (BE) 2019-10-16 — — EP claimed
WO-2018211126-A1 DIAGNOSTIC TEST FOR DISTINGUISHING THE SMOKING STATUS OF A SUBJECT PHILIP MORRIS PRODUCTS S.A. (CH) 2018-11-22 — — WO claimed
US-20160279043-A1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS DENTALMED PHARM HOLDING LTD. (BE) 2016-09-29 — — US claimed
EP-2976061-A1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS Dentalmed Pharm Holding Ltd. (BE) 2016-01-27 — — EP claimed
WO-2014147613-A1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS DENTALMED PHARM HOLDING LTD. (BE) 2014-09-25 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028489-A1 SUPPORTED POLYMERIZATION INHIBITORS AND THEIR USE IN CURABLE COMPOSITIONS FOR 3D PRINTING ILK, MTCL3, MARK3 MAPT 100/4885ALDH1A1 2419/4885KDM4E 152/4885
US-20160279043-A1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS SIRT3, NNT, SIRT1 MAPT 3459/4885ALDH1A1 2645/4885KDM4E 3614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback